Objective To observe the efficiency of IVTA for the treatment of ME by spectra domain OCT. Methods A total of 46 eyes with ME were observed. All patients were diagnosed expecially by FFA and spectra domain OCT, with vision≤0.6 and CMT≥250μm. All received intravitreal injection of 4mg/0.1mL of TA. BCVA, CMT, CMV, and AVG were compared before and after treatment. Results After treatment, BCVA were significantly increased in each time point(P=0.000), BCVA in 4 (BCVA=0.3916±0.2564), 8 (BCVA=0.5668±0.1835), 12 (BCVA=0.5314±0.1996) weeks, were similar. After treatment, compared with baseline, the changes of CMT, CMV and AVG were significantly increased in each time point (P=0.000). Conclusion IVTA for the treatment of ME could increase BCVA and reduce ME instinctively. CMT can reveal the effect of treatment better than CMV and AVG.% 目的通过频域OCT观察玻璃体腔注射曲安奈德(TA)治疗黄斑水肿的临床疗效.方法回顾性分析46例眼科常规检查及经FFA和频域OCT查均确诊为黄斑水肿,视力≤0.6,黄斑中心凹厚度(CMT)≥250μm的患者46只眼纳入观察,进行玻璃体腔注射TA(4mg,0.1mL)治疗.比较治疗前和治疗后1d及1,2,4,8,12,24周最佳矫正视力(BCVA)改变；治疗前和治疗后1,2,4,8,12,24周的黄斑中心凹厚度(CMT)、黄斑中心容积(CMV)、黄斑区平均厚度(AVG)的改变.结果在治疗后视显提高,术后各时间点(P=0.000)均具有统计学意义,BCVA各点分别为：4周(0.3916±0.2564)；8周(0.5668±0.1835)；12周(0.5314±0.1996),视力基本持平,24周(0.3853±0.2024)缓慢下降.CMT方面,较基线比,在治疗后CMT明显降低,术后各时间点(P=0.000)均具有统计学意义.与基线相比, CMV、AVG两具有显著改变.BCVA分别与CMT、CMV、AVG呈负相关.结论玻璃体腔注射TA治疗黄斑水肿均可明显改善,减轻黄斑水肿.BCVA分别与CMT、CMV、AVG呈负相关,CMV、AVG也可反映治疗效果,但敏感性不及CMT
展开▼
